Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database

  • Naffouje, Samer A. (Department of General Surgery, University of Illinois Hospital and Health Sciences System) ;
  • Salti, George I. (Department of Surgical Oncology, Edward Cancer Center)
  • Received : 2017.08.05
  • Accepted : 2017.11.20
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: The extent of lymphadenectomy in the surgical treatment of gastric cancer is a topic of controversy among surgeons. This study was conducted to analyze the American National Cancer Database (NCDB) and conclude the optimal extent of lymphadenectomy for gastric adenocarcinoma. Methods: The NCDB for gastric cancer was utilized. Patients who received at least a partial gastrectomy were included. Patients with metastatic disease, unknown TNM stages, R1/R2 resection, or treated with a palliative intent were excluded. Joinpoint regression was used to identify the extent of lymphadenectomy that reflects the optimal survival. Cox regression analysis and Bayesian information criterion were used to identify significant survival predictors. Kaplan-Meier was applied to study overall survival and stage migration. Results: 40,281 patients of 168,377 met the inclusion criteria. Joinpoint analysis showed that dissection of 29 nodes provides the optimal median survival for the overall population. Regression analysis reported the cutoff ${\geq}29$ to have a better fit in the prognostic model than that of ${\geq}15$. Dissection of ${\geq}29$ nodes in the higher stages provides a comparable overall survival to the immediately lower stage. Nonetheless, the retrieval of ${\geq}15$ nodes proved to be adequate for staging without a significant stage migration compared to ${\geq}29$ nodes. Conclusion: The extent of lymphadenectomy in gastric adenocarcinoma is a marker of improved resection which reflects in a longer overall survival. Our analysis concludes that the dissection of ${\geq}15$ nodes is adequate for staging. However, the dissection of 29 nodes might be needed to provide a significantly improved survival.

Keywords

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
  2. Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 2011;17:4421-4428. https://doi.org/10.3748/wjg.v17.i39.4421
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. https://doi.org/10.3322/caac.21332
  4. International Agency for Research on Cancer; World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Lyon: International Agency for Research on Cancer; 2014 [cited 2017 Oct 20]. Available from: http://globocan.iarc.fr.
  5. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res Treat 2013;45:15-21. https://doi.org/10.4143/crt.2013.45.1.15
  6. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-315. https://doi.org/10.1016/S1470-2045(06)70623-4
  7. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-425. https://doi.org/10.1007/BF01655804
  8. de Aretxabala X, Konishi K, Yonemura Y, Ueno K, Yagi M, Noguchi M, et al. Node dissection in gastric cancer. Br J Surg 1987;74:770-773. https://doi.org/10.1002/bjs.1800740904
  9. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-999. https://doi.org/10.1016/S0140-6736(96)90144-0
  10. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748. https://doi.org/10.1016/S0140-6736(95)90637-1
  11. National Comprehensive Cancer Network (US). NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer, Version 3. 2016. Fort Washington (PA): National Comprehensive Cancer Network, 2016.
  12. Wang J, Dang P, Raut CP, Pandalai PK, Maduekwe UN, Rattner DW, et al. Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg 2012;255:478-485. https://doi.org/10.1097/SLA.0b013e31824857e2
  13. Bunt AM, Hermans J, Smit VT, van de Velde CJ, Fleuren GJ, Bruijn JA. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995;13:19-25. https://doi.org/10.1200/JCO.1995.13.1.19
  14. Putchakayala K, Difronzo LA. D2 lymph node dissection improves staging in patients with gastric adenocarcinoma. Am Surg 2011;77:1326-1329.
  15. American Cancer Society. Survival Rates for Stomach Cancer, by Stage. Atlanta (GA): American Cancer Society, 2016.
  16. Lee HK, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg 2001;88:1408-1412. https://doi.org/10.1046/j.0007-1323.2001.01875.x
  17. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449-461. https://doi.org/10.1097/00000658-199810000-00002
  18. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563. https://doi.org/10.1002/bjs.5353
  19. Biffi R, Chiappa A, Luca F, Pozzi S, Lo Faso F, Cenciarelli S, et al. Extended lymph node dissection without routine spleno- pancreatectomy for treatment of gastric cancer: low morbidity and mortality rates in a single center series of 250 patients. J Surg Oncol 2006;93:394-400. https://doi.org/10.1002/jso.20495
  20. Uyama I, Ogiwara H, Takahara T, Kikuchi K, Iida S, Kubota T, et al. Spleen- and pancreas-preserving total gastrectomy with superextended lymphadenectomy including dissection of the para-aortic lymph nodes for gastric cancer. J Surg Oncol 1996;63:268-270. https://doi.org/10.1002/(SICI)1096-9098(199612)63:4<268::AID-JSO10>3.0.CO;2-#
  21. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg 2000;232:362-371. https://doi.org/10.1097/00000658-200009000-00008
  22. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 2010;17:3077-3079. https://doi.org/10.1245/s10434-010-1362-z
  23. Woo Y, Goldner B, Ituarte P, Lee B, Melstrom L, Son T, et al. Lymphadenectomy with optimum of 29 lymph nodes retrieved associated with improved survival in advanced gastric cancer: a 25,000-patient international database study. J Am Coll Surg 2017;224:546-555. https://doi.org/10.1016/j.jamcollsurg.2016.12.015
  24. National Cancer Institute (US). Joinpoint Regression Program, Version 4.4.0.0 (Jan 4, 2017). Rockville (MD): National Cancer Institute, 2017.
  25. Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014;101:23-31. https://doi.org/10.1002/bjs.9345
  26. Reid-Lombardo KM, Gay G, Patel-Parekh L, Ajani JA, Donohue JHGastric Patient Care Evaluation Group from the Commission on Cancer. Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from the National Cancer Data Base. J Gastrointest Surg 2007;11:410-419. https://doi.org/10.1007/s11605-006-0040-8
  27. Mullaney PJ, Wadley MS, Hyde C, Wyatt J, Lawrence G, Hallissey MT, et al. Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Br J Surg 2002;89:1405-1408. https://doi.org/10.1046/j.1365-2168.2002.02262.x
  28. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137. https://doi.org/10.1056/NEJMsa012337
  29. Smith DL, Elting LS, Learn PA, Raut CP, Mansfield PF. Factors influencing the volume-outcome relationship in gastrectomies: a population-based study. Ann Surg Oncol 2007;14:1846-1852. https://doi.org/10.1245/s10434-007-9381-0
  30. Schmidt B, Yoon SS. D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol 2013;107:259-264. https://doi.org/10.1002/jso.23127
  31. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-2773. https://doi.org/10.1200/JCO.2004.10.184
  32. Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005;92:1099-1102. https://doi.org/10.1002/bjs.4952

Cited by

  1. Modularized laparoscopic regional en bloc mesogastrium excision (rEME) based on membrane anatomy for distal gastric cancer vol.32, pp.11, 2017, https://doi.org/10.1007/s00464-018-6375-x
  2. Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy vol.106, pp.9, 2019, https://doi.org/10.1002/bjs.11181
  3. Performance of a machine learning-based decision model to help clinicians decide the extent of lymphadenectomy (D1 vs. D2) in gastric cancer before surgical resection vol.44, pp.9, 2017, https://doi.org/10.1007/s00261-019-02098-w
  4. Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy vol.19, pp.1, 2017, https://doi.org/10.1186/s12885-019-6075-5
  5. Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer vol.126, pp.6, 2020, https://doi.org/10.1002/cncr.32660
  6. Positive node‐ratio in curative‐intent treatment for gastric cancer is a strong independent prognostic factor for 5‐year overall survival vol.121, pp.5, 2017, https://doi.org/10.1002/jso.25755
  7. Laparoscopic Versus Open D2 Gastrectomy for Gastric Cancer: A Case-Matched Comparative Study vol.30, pp.7, 2020, https://doi.org/10.1089/lap.2020.0023
  8. Laparoscopic Compared with Open D2 Gastrectomy on Perioperative and Long-Term, Stage-Stratified Oncological Outcomes for Gastric Cancer: A Propensity Score-Matched Analysis of the IMIGASTRIC Database vol.13, pp.18, 2017, https://doi.org/10.3390/cancers13184526
  9. Extent of gastrectomy and lymphadenectomy for gastric adenocarcinoma vol.40, pp.None, 2017, https://doi.org/10.1016/j.suronc.2021.101689